Companies › Betta Pharmaceuticals
9 active drug programs in 27 registered trials: 13 Phase 1, 13 Phase 2, 1 Phase 3; Oncology, Other, Gastroenterology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Befotertinib EGFR tyrosine kinase inhibitor | EGFR | Phase 3 | Non-Small Cell Lung Cancer; NSCLC; DDI (Drug-Drug Interaction); Non-small Cell Lung Cancer (NSCLC) … | Apr 2027 |
| BPI-371153 PD-L1 inhibitor | CD274 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| X-82 Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 1 | DDI (Drug-Drug Interaction); Hepatic Impairment (HI); Advanced Non-small Cell Lung Cancer (NSCLC); Vorolanib … | Jan 2027 |
| CFT8919 EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | Non-Small Cell Lung Cancer With EGFR Mutation | Jun 2027 |
| MCLA-129 bispecific antibody targeting EGFR and cMET | EGFR, MET | Phase 1 | Solid Tumor; Solid Advanced Tumor | Apr 2028 |
| BPI-572270 RAS mutant inhibitor | – | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Dec 2028 |
| Ensartinib ALK tyrosine kinase receptor inhibitor | ALK | Phase 1 | Solid Advanced Tumor; Nonsmall Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Malignant Solid Neoplasm … | Feb 2029 |
| BPI-16350 | – | Phase 1 | Advanced Solid Cancer | – |
| BPI-460372 | – | Phase 1 | Advanced Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05789602 | BPI-460372 | Phase 1 | Advanced Solid Tumor | Oncology | Apr 2025 |
| NCT03753685 | Ensartinib | Phase 2 | Nonsmall Cell Lung Cancer | Oncology | Jun 2025 |
| NCT03791112 | BPI-16350 | Phase 1 | Advanced Solid Cancer | Oncology | Dec 2025 |
| NCT06728852 | X-82 | Phase 2 | Advanced Non-small Cell Lung Cancer (NSCLC) | Oncology | Dec 2026 |
| NCT05491811 | Ensartinib | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05341557 | BPI-371153 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT07386158 | X-82 | Phase 2 | Vorolanib | Oncology | Dec 2026 |
| NCT03155620 | Ensartinib | Phase 2 | Advanced Malignant Solid Neoplasm | Oncology | Jan 2027 |
| NCT07809789 | X-82 | Phase 1 | DDI (Drug-Drug Interaction) | Other | Jan 2027 |
| NCT03420508 | Ensartinib | Phase 2 | Melanoma | Oncology | Jan 2027 |
| NCT05241028 | Ensartinib | Phase 2 | Non-small Cell Lung Cancer | Oncology | Feb 2027 |
| NCT07809815 | Befotertinib | Phase 1 | DDI (Drug-Drug Interaction) | Other | Apr 2027 |
| NCT06641609 | CFT8919 | Phase 1 | Non-Small Cell Lung Cancer With EGFR Mutation | Oncology | Jun 2027 |
| NCT07809802 | X-82 | Phase 1 | Hepatic Impairment (HI) | Gastroenterology | Jun 2027 |
| NCT04837716 | Ensartinib | Phase 1 | Metastatic Lung Non-Small Cell Carcinoma | Oncology | Sep 2027 |
| NCT03213652 | Ensartinib | Phase 2 | Advanced Malignant Solid Neoplasm | Oncology | Oct 2027 |
| NCT06730672 | X-82 | Phase 2 | Renal Cell Carcinoma Stage I | Oncology | Dec 2027 |
| NCT06728865 | Befotertinib | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Feb 2028 |
| NCT07354061 | Ensartinib | Phase 1 | NSCLC (Non-small Cell Lung Cancer) | Oncology | Mar 2028 |
| NCT04930432 | MCLA-129 | Phase 1 | Solid Tumor | Oncology | Apr 2028 |
| NCT06041776 | Befotertinib | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Apr 2028 |
| NCT07181499 | Befotertinib | Phase 2 | NSCLC | Oncology | Nov 2028 |
| NCT07435038 | BPI-572270 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Dec 2028 |
| NCT07448116 | MCLA-129 | Phase 1 | Solid Advanced Tumor | Oncology | Feb 2029 |
| NCT07448116 | Ensartinib | Phase 1 | Solid Advanced Tumor | Oncology | Feb 2029 |
| NCT07047001 | X-82 | Phase 2 | Renal Cell Carcinoma (RCC) | Oncology | Jun 2029 |
| NCT07709585 | Befotertinib | Phase 2 | Advanced Non-small Cell Lung Cancer (NSCLC) | Oncology | Jul 2030 |
Avistone Biotechnology Abbisko Therapeutics Nanjing Sanhome Pharmaceutical Pierre Fabre Medicament Hansoh BioMedical R&D Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.